Coherus Biosciences: Strategic Positioning and Growth Potential with Loqtorzi Leading the Charge
I'm PortAI, I can summarize articles.
Analyst Jason McCarthy from Maxim Group maintains a Buy rating on Coherus Biosciences with a $4.00 price target, citing strategic positioning and growth potential. Loqtorzi's Phase 3 study shows improved survival rates in nasopharyngeal carcinoma patients. Strategic partnerships and collaborations enhance market opportunities, valued at $150M-200M. McCarthy's valuation model supports a positive outlook despite his average return of -8.6% and a 36.35% success rate on recommended stocks.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments